| 7.06 0.24 (3.52%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.29 | 1-year : | 9.68 |
| Resists | First : | 7.09 | Second : | 8.29 |
| Pivot price | 6.5  |
|||
| Supports | First : | 6.18 | Second : | 5.61 |
| MAs | MA(5) : | 6.73 |
MA(20) : | 6.45 |
| MA(100) : | 6.87  |
MA(250) : | 5.88 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.6 |
D(3) : | 71.3 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 9.96 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XBIT ] has closed below upper band by 11.6%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.08 - 7.1 | 7.1 - 7.14 |
| Low: | 6.68 - 6.71 | 6.71 - 6.74 |
| Close: | 7 - 7.05 | 7.05 - 7.11 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Fri, 13 Sep 2024
XBiotech (NASDAQ:XBIT) Stock Passes Above Fifty Day Moving Average of $6.47 - MarketBeat
Fri, 13 Sep 2024
XBiotech (NASDAQ:XBIT) Stock Crosses Above Fifty Day Moving Average of $6.47 - Defense World
Fri, 30 Aug 2024
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load? - Simply Wall St
Wed, 10 Jan 2024
symbol__ Stock Quote Price and Forecast - CNN
Tue, 08 Aug 2023
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - Yahoo Finance
Wed, 24 Oct 2018
XBiotech Announces Dismissal of Securities Class Action Suit - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 35.1 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 905 (K) |
| Shares Short P.Month | 946 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.9 % |
| Return on Equity (ttm) | -16.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -6.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|